GW Henssler & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

GW Henssler & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	20,690 +50	+0.2%	+$22.2K	0.46%	76
2026 Q1	$9.22M	Buy	20,640 +1,806	+10%	+$842K	0.43%	86
2025 Q4	$8.54M	Sell	18,834 -3,957	-17%	-$1.71M	0.41%	83
2025 Q3	$8.93M	Buy	22,791 +28	+0.1%	+$11.7K	0.45%	80
2025 Q2	$10.1M	Sell	22,763 -48	-0.2%	-$22.1K	0.54%	74
2025 Q1	$11.1M	Sell	22,811 -1,405	-6%	-$655K	0.63%	62
2024 Q4	$11.3M	Sell	24,216 -257	-1%	-$119K	0.65%	59
2024 Q3	$11.4M	Buy	+24,473	New	+$11.8M	0.64%	59

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GW Henssler & Associates's VRTX Position: Q2 2026 in Review

GW Henssler & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 0.24% in Q2 2026, buying an estimated $22.2K and bringing the position to 20,690 shares worth $10.3M. The position accounts for 0.46% of the portfolio, ranked #76.

GW Henssler & Associates first reported a position in VRTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $11.4M in Q3 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

GW Henssler & Associates held 20,690 shares of Vertex Pharmaceuticals worth $10.3M as of Q2 2026.
GW Henssler & Associates bought 50 Vertex Pharmaceuticals shares in Q2 2026, an estimated $22.2K.
Vertex Pharmaceuticals made up 0.46% of GW Henssler & Associates's portfolio in Q2 2026, its #76 holding.
GW Henssler & Associates first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
GW Henssler & Associates's Vertex Pharmaceuticals position peaked at $11.4M in Q3 2024.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on GW Henssler & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.